PSA, PSAD Less Predictive of Aggressive PCa in Black Men
Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.
Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.
From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.
Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.
Following the 2012 USPSTF recommendation against PSA screening in populations, rates of radical prostatectomy and biopsy have become significantly less common.
A PSA level of 1.5 ng/mL or higher should prompt primary care physicians to refer patients to a urologist for further evaluation.
In a PREVAIL trial post hoc analysis, nearly one fourth of men on enzalutamide had radiographic progression despite non-rising PSA.
After 20 years, the prostate cancer mortality rate was 0.7% for men with a PSA level of 10 ng/mL or less and benign initial biopsy results.
Decreases in use of screening following USPSTF recommendations against routine PSA screening.
Clinicians now have tools for improving prostate cancer screening and risk stratification.
Shows the strongest correlation between biochemical recurrence and subsequent systemic progression.